NeuroRx® Changes Name to Neurotherapeutics
Publication provides critical reviews in therapy of neurological disorders
Philadelphia, 04 January 2007 - NeuroRx®, the official journal of the American Society for Experimental NeuroTherapeutics (ASENT), published by Elsevier, will be changing its name to Neurotherapeutics as of the January 2007 issue. Elsevier, the Editor-in-Chief and Editorial Board for NeuroRx® and the ASENT Board members worked closely together in 2006 to develop a new name to reinforce the true focus of the journal.
Neurotherapeutics is a unique publication providing critical reviews on selected topics in therapy of neurological disorders. Each quarterly issue focuses on dedicated topic(s), with internationally recognized authorities sharing their in-depth understanding. Neurotherapeutics offers a multidisciplinary perspective on high-profile topics in neurotherapeutics, taking in not just the scientific issues but also their social and ethical ramifications.
"Neurotherapeutics more clearly reflects the intended meaning of the journal title and positions it more accurately in the field," said Editor-in-Chief, Alan I. Faden, MD.
Citations for prior issues of the journal, which is indexed by PubMed Central and MEDLINE, will be available under both NeuroRx® and Neurotherapeutics.
# # #
The purpose of the American Society for Experimental NeuroTherapeutics is to provide a forum for broadly defined interest areas of academia, government, industry and advocacy concerned with the field of neurotherapeutics; to promote dialogue, understanding and cooperation among the interested groups; to develop information and seek consensus on matters germane to the organization’s mission; and to organize education and training for healthcare practitioners, biomedical scientists and officials participating in the neurotherapeutics field. Visit the Society's website at www.asent.org.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com